Search Results for "Payers"

The infrastructure bill includes a drug waste provision from the Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act, which requires manufacturers to rebate the amount wasted back to CMS. An estimated $3 billion over 10 years can be recouped and invested in roads, bridges, and other infrastructure initiatives.

Meanwhile, pharmaceutical companies would stand to make a lot more money.

Numerous articles and reports have trumpeted biosimilar market growth, but it's critical we do not lose sight of the sole objective for creating the biosimilar market: to reduce the cost of older biologic drugs for society and taxpayers.

Value-based pricing has emerged as an alternative to prices determined by what the market will bear. But which agreements are truly "value-based"?

The launch price for one-time gene therapy Zolgensma presents various implications.

An overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.

The Drug Pricing Lab takes issue with The New York Times "Fact Check" on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.

An alternative payment model is proposed to support a population-level payment paradigm.

Supply chain intermediaries, or “middlemen,” are being blamed for capturing much of the money that is often categorized as drug spending.

Research tells us 9% of hospitals would lose their 340B eligibility under Trump's drug pricing plan. Essentially all are in Medicaid expansion states.

A taxonomy of the features that make a payment model truly value-based.

Dana Goldman and Darius Lakdawalla look to Major League baseball to explain the drug pricing problem.

What steps are needed to make outcomes-based contracting a value-based approach?

Drug prices in other high income countries for the 20 top selling drugs globally make up less than half of U.S. net drug prices.

Major drug companies have raised prices over the past five years, sometimes doubling them, a Reuters analysis found.

When Martin Shkreli of Turing Pharmaceuticals raised the price for Daraprim by 5,455%, he put drug pricing on the agenda for the leading 2016 presidential candidates.